Eikon Therapeutics IPO

eikontx.comHealthcare / BioTech & Pharma

Eikon Therapeutics, based in Hayward, Calif., was founded in 2019 by Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian. In 2014, Betzig shared the Nobel Prize in Chemistry. Robert Perlmutter is the company’s chairman and CEO. Eikon, which was last valued on January 2022 at $3.1 billion, is a drug discovery and development company that leverages superior engineering and high-performance computing to analyze single molecule protein behavior in living cells.

In January 2022, the company raised $525 million in Series B financing led by more than a dozen investors including T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, UC Investments, Soros Capital and Schroders Capital.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Buy or sell Eikon Therapeutics stock Learn more about Eikon Therapeutics stock

Learn more about Eikon Therapeutics

Is Eikon Therapeutics a publicly traded company?

Eikon Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Eikon Therapeutics go IPO?

Eikon Therapeutics has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Eikon Therapeutics's IPO price?

The IPO price for Eikon Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Eikon Therapeutics pre-IPO?

Eikon Therapeutics is privately held company and is not publicly traded, therefor investing in Eikon Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Eikon Therapeutics shares?

To determine the value of your Eikon Therapeutics shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Eikon Therapeutics shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Eikon Therapeutics before it goes public?

Yes, you can seek to sell shares in Eikon Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is Eikon Therapeutics's funding to date?

Eikon Therapeutics has raised $1.21B to date.

When was Eikon Therapeutics founded?

Eikon Therapeutics was founded in 2019.

Who are Eikon Therapeutics's major investors?

General Catalyst

Lux Capital

AME Cloud Ventures

Horizons Ventures

Innovation Endeavors

The Column Group

Eikon Therapeutics funding rounds and last known valuation

Date	Funding Round	Funding Raised	Price per Share	Last Known Valuation
5/16/2023	Series C	$535MM raised	$XXX.XX	$XXX.XX
1/6/2022	Series B	$525MM raised	$XXX.XX	$XXX.XX
5/5/2021	Series A and A-1	$150.54MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.